Literature DB >> 15213143

Characterization of a complement-binding protein, DRS, from strains of Streptococcus pyogenes containing the emm12 and emm55 genes.

Michael Binks1, K S Sriprakash.   

Abstract

An extracellular protein of Streptococcus pyogenes, streptococcal inhibitor of complement (SIC), and its variant, called DRS (distantly related to SIC), are expressed by some S. pyogenes strains. SIC from type 1 (M1) isolates of S. pyogenes interferes with complement-mediated cell lysis, reportedly via its interaction with complement proteins. In this study we demonstrate that S. pyogenes strains carrying emm12 and emm55 (the genes for the M12 and M55 proteins, respectively) express and secrete DRS. This protein, like SIC, binds to the C6 and C7 complement proteins, and competition enzyme-linked immunosorbent assay experiments demonstrate that DRS competes with SIC for C6 and C7 binding. Similarly, SIC competes with DRS for binding to the complement proteins. Despite this, the recombinant DRS preparation showed no significant effect on complement function, as determined by lysis of sensitized sheep erythrocytes. Furthermore, the presence of DRS is not inhibitory to SIC activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213143      PMCID: PMC427425          DOI: 10.1128/IAI.72.7.3981-3986.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Genomic location and variation of the gene for CRS, a complement binding protein in the M57 strains of Streptococcus pyogenes.

Authors:  Michael Binks; David McMillan; Kadaba S Sriprakash
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides.

Authors:  Inga-Maria Frick; Per Akesson; Magnus Rasmussen; Artur Schmidtchen; Lars Björck
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

3.  Antigenic streptococcal components in acute glomerulonephritis.

Authors:  G Treser; M Semar; M McVicar; M Franklin; A Ty; I Sagel; K Lange
Journal:  Science       Date:  1969-02-14       Impact factor: 47.728

4.  Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases.

Authors:  S Chatellier; N Ihendyane; R G Kansal; F Khambaty; H Basma; A Norrby-Teglund; D E Low; A McGeer; M Kotb
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

Review 5.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

6.  Identification and immunogenicity of group A Streptococcus culture supernatant proteins.

Authors:  B Lei; S Mackie; S Lukomski; J M Musser
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics.

Authors:  N P Hoe; P Kordari; R Cole; M Liu; T Palzkill; W Huang; D McLellan; G J Adams; M Hu; J Vuopio-Varkila; T R Cate; M E Pichichero; K M Edwards; J Eskola; D E Low; J M Musser
Journal:  J Infect Dis       Date:  2000-10-03       Impact factor: 5.226

8.  Characterization of consecutive Streptococcus pyogenes isolates from patients with pharyngitis and bacteriological treatment failure: special reference to prtF1 and sic / drs.

Authors:  C M Brandt; F Allerberger; B Spellerberg; R Holland; R Lütticken; G Haase
Journal:  J Infect Dis       Date:  2001-01-24       Impact factor: 5.226

9.  Association of the prtF1 gene (encoding fibronectin-binding protein F1) and the sic gene (encoding the streptococcal inhibitor of complement) with emm types of group A streptococci isolated from Japanese children with pharyngitis.

Authors:  Xiaoming Ma; Hideaki Kikuta; Nobuhisa Ishiguro; Mikio Yoshioka; Takashi Ebihara; Teiko Murai; Intetu Kobayashi; Kunihiko Kobayashi
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme.

Authors:  Barbara A Fernie-King; David J Seilly; Alexandra Davies; Peter J Lachmann
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  10 in total

1.  DRS is far less divergent than streptococcal inhibitor of complement of group A streptococcus.

Authors:  Vivek Sagar; Rajesh Kumar; Nirmal K Ganguly; Thangam Menon; Anuradha Chakraborti
Journal:  J Bacteriol       Date:  2007-01-19       Impact factor: 3.490

2.  Sequence diversity of sicG among group C and G Streptococcus dysgalactiae subspecies equisimilis isolates associated with human infections in western Norway.

Authors:  O Oppegaard; H Mylvaganam; S Skrede; N Langeland; B R Kittang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-10       Impact factor: 3.267

3.  Seropositivity for Antibodies to DRS-G, a Virulence Factor from Streptococcus dysgalactiae subsp. equisimilis, Is an Independent Risk Factor for Poststreptococcus Glomerulonephritis and Chronic Kidney Disease in Mumbai, India.

Authors:  Gouri P Hule; Mohan G Karmarkar; Ainslie Cameron; Niwrutti Hase; Uday Khopkar; Preeti R Mehta; Celia L McNeilly; David McMillan; Kadaba S Sriprakash
Journal:  Clin Vaccine Immunol       Date:  2015-06-17

4.  Selective MyD88-dependent pathway inhibition by the cyanobacterial natural product malyngamide F acetate.

Authors:  Francisco A Villa; Kelly Lieske; Lena Gerwick
Journal:  Eur J Pharmacol       Date:  2009-12-16       Impact factor: 4.432

5.  Seroreactivity against streptococcal DRS (distantly related to SIC) protein is a predictor for end-stage renal failure.

Authors:  Virginia A F Boon; James L Munro; George W Kan; James Burnell; Richard Speare
Journal:  Clin Vaccine Immunol       Date:  2008-08-06

Review 6.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

7.  DrsG from Streptococcus dysgalactiae subsp. equisimilis inhibits the antimicrobial peptide LL-37.

Authors:  Danielle Smyth; Ainslie Cameron; Mark R Davies; Celia McNeilly; Louise Hafner; Kadaba S Sriprakash; David J McMillan
Journal:  Infect Immun       Date:  2014-03-24       Impact factor: 3.441

8.  Complete genome sequencing and analysis of a Lancefield group G Streptococcus dysgalactiae subsp. equisimilis strain causing streptococcal toxic shock syndrome (STSS).

Authors:  Yumi Shimomura; Kayo Okumura; Somay Yamagata Murayama; Junji Yagi; Kimiko Ubukata; Teruo Kirikae; Tohru Miyoshi-Akiyama
Journal:  BMC Genomics       Date:  2011-01-11       Impact factor: 3.969

9.  Streptococcal protein SIC activates monocytes and induces inflammation.

Authors:  Ariane Neumann; Lotta Happonen; Christofer Karlsson; Wael Bahnan; Inga-Maria Frick; Lars Björck
Journal:  iScience       Date:  2021-03-20

10.  Seroprevalence of Streptococcal Inhibitor of Complement (SIC) suggests association of streptococcal infection with chronic kidney disease.

Authors:  Mohan Ganesh Karmarkar; Gouri Pandharinath Hule; Niwrutti Khandu Hase; Preeti Rajeev Mehta; Scott Robert Walter; Kadaba Srinivasa Sriprakash
Journal:  BMC Nephrol       Date:  2013-05-06       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.